Evidence map›Paper›PMID 33095766›Full record

ArticlePLoS neglected tropical diseases2020

Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples.

Rebecca Surtees, Daniel Stern, Katharina Ahrens, Nicole Kromarek, Angelika Lander, Petra Kreher, Sabrina Weiss, Roger Hewson, Emma K Punch, John N Barr and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Rebecca SurteesBiosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0003-0265-8407
Daniel SternBiological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0001-9057-4283
Katharina AhrensBiosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0002-6621-6379
Nicole KromarekBiosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
Angelika LanderBiosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
Petra KreherBiosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
Sabrina WeissInstitute of Virology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.ORCID 0000-0002-4835-3695
Roger HewsonVirology and Pathogenesis Group, National Infection Service, Public Health England, Porton Down, United Kingdom.
Emma K PunchSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, United Kingdom.ORCID 0000-0002-5477-6619
John N BarrSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, United Kingdom.ORCID 0000-0002-9035-2039
Peter T WitkowskiInstitute of Virology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.ORCID 0000-0002-6167-8945
Emmanuel Couacy-HymannLaboratoire National d'Appui au Développement Agricole, Bingerville, Ivory Coast.
Andrea MarziLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, United States of America.ORCID 0000-0003-0186-9587
Brigitte G DornerBiological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0002-5100-2546
Andreas KurthBiosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.ORCID 0000-0002-9660-9878
Robert Koch Institute · DEHumboldt-Universität zu Berlin · DEUniversity of Leeds · GBLaboratoire National d'Appui au Développement Agricole · CINational Institutes of Health · USPublic Health England · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surveillance of highly pathogenic viruses circulating in both human and animal populations is crucial to unveil endemic infections and potential zoonotic reservoirs. Monitoring the burden of disease by serological assay could be used as an early warning system for imminent outbreaks as an increased seroprevalance often precedes larger outbreaks. However, the multitude of highly pathogenic viruses necessitates the need to identify specific antibodies against several targets from both humans as well as from potential reservoir animals such as bats. In order to address this, we have developed a broadly reactive multiplex microsphere immunoassay (MMIA) for the detection of antibodies against several highly pathogenic viruses from both humans and animals. To this aim, nucleoproteins (NP) of Ebola virus (EBOV), Marburg virus (MARV) and nucleocapsid proteins (NP) of Crimean-Congo haemorrhagic fever virus, Rift Valley fever virus and Dobrava-Belgrade hantavirus were employed in a 5-plex assay for IgG detection. After optimisation, specific binding to each respective NP was shown by testing sera from humans and non-human primates with known infection status. The usefulness of our assay for serosurveillance was shown by determining the immune response against the NP antigens in a panel of 129 human serum samples collected in Guinea between 2011 and 2012 in comparison to a panel of 88 sera from the German blood bank. We found good agreement between our MMIA and commercial or in-house reference methods by ELISA or IIFT with statistically significant higher binding to both EBOV NP and MARV NP coupled microspheres in the Guinea panel. Finally, the MMIA was successfully adapted to detect antibodies from bats that had been inoculated with EBOV- and MARV- virus-like particles, highlighting the versatility of this technique and potentially enabling the monitoring of wildlife as well as human populations with this assay. We were thus able to develop and validate a sensitive and broadly reactive high-throughput serological assay which could be used as a screening tool to detect antibodies against several highly pathogenic viruses.

Indexed as

MicrospheresAnimalsAntibodies, ViralChiropteraHumansImmunoassayNucleocapsid ProteinsPrimatesVirus DiseasesAntibodies, ViralNucleocapsid Proteins

Identifiers

PMID33095766
PMCPMC7641473
OpenAlexW3094401051

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.